

Learning Objectives for EduCon 2022 Virtual

February 3

ACPE #0129-9999-22-016-H04-P 0.1 CEU

ACPE #0129-9999-22-016-H04-T 0.1 CEU

Knowledge-based activity

When the DEA Comes Calling: Preparing for and Managing that Inspection

Larry Houck

At the completion of this activity, the participant will be able to:

1. outline what they must do to prepare for and manage Drug Enforcement Administration (“DEA”) inspections;
2. describe what to expect during a DEA inspection;
3. recognize extent of DEA inspection authority;
4. explain scope of a DEA Inspection, including review of policies and procedures, accountability audit, and review of records, reports and security;
5. list inspection nuts and bolts, including inspection do’s and don’ts and importance of conducting a post-inspection mirror audit; and
6. discuss DEA enforcement actions.

ACPE #0129-9999-22-017-H07-P 0.1 CEU

ACPE #0129-9999-22-017-H07-T 0.1 CEU

Knowledge-based activity

Veterinary Compounding: Considerations & Clinical Pearls

Deborah Clark, R.Ph.

At the completion of this activity, the participant will be able to:

1. list several considerations that should be addressed when choosing a route of administration and dosage form for a given species;
2. list toxicities that should be considered when choosing a commercially available drug product or when formulating a compounded product for more common species;
3. list appropriate dosage forms for the canine, feline and equine patient; and
4. list unique dosage form options that may give a better therapeutic outcome in certain species.

ACPE #0129-9999-22-018-H04-P 0.1 CEU

ACPE #0129-9999-22-018-H04-T 0.1 CEU

Knowledge-based activity

Compounder Ethics: The Code as Compliance Strategy

Barbara Exum

At the completion of this activity, the participant will be able to:

1. define ethics and discuss characteristics of ethical behavior in the practice of pharmacy;
2. review the new code of ethics adopted by Alliance for Pharmacy Compounding, *The Pharmacy Compounding Professional’s Code of Ethics*;
3. discuss ethical principles as they relate to compounders; and
4. describe frameworks used in ethical decision-making when confronted with ethical dilemmas.

ACPE #0129-9999-22-019-H04-P **0.1 CEU**

ACPE #0129-9999-22-019-H04-T **0.1 CEU**

Knowledge-based activity

Cultural Competency & Bias Training

Denise Frank, BPharm, R.Ph., FACA

At the completion of this activity, the participant will be able to:

1. describe the background and purpose of Section 1557, “Nondiscrimination in Health Programs and Activities”;
2. identify the key provisions, including enforcement and consequences of noncompliance;
3. recognize the types of discrimination, and examples of discrimination; and
4. develop a plan for your work setting to become compliant.

ACPE #0129-9999-22-020-H04-P **0.1 CEU**

ACPE #0129-9999-22-020-H04-T **0.1 CEU**

Knowledge-based activity

R&D Roundtable: How Compounders are Aiding Medical Research

Facilitator: Alexander Pytlarz, R.Ph.; Panelists: Linda McElhiney, R.Ph.; Joe Navarra, R.Ph.; and David Mastropietro, R.Ph., Ph.D.

At the completion of this activity, the participant will be able to:

1. recognize the range of medical research projects in which compounders are engaged and can be engaged;
2. demonstrate an understanding of the research protocols under which compounders can engage in supporting medical research projects; and
3. explain how to cultivate relationships with medical research and identify R&D opportunities related to compounding.

ACPE #0129-9999-22-021-H04-P **0.1 CEU**

ACPE #0129-9999-22-021-H04-T **0.1 CEU**

Knowledge-based activity

Implementing Pharmacogenomic Testing in Your Practice

Peter Clapp, Ph.D. and Lisa Faast, PharmD

At the completion of this activity, the participant will be able to:

1. define and explain the use of single nucleotide polymorphisms (SNPs) in pharmacogenetic analyses;
2. describe possible consequences of metabolic enzyme polymorphism on drug disposition or activity, given specific examples;
3. identify potential patients to recommend PGx testing for;
4. recognize proper compensation models for PGx services;
5. explain how to apply a PGx strategy to your compounding formula choices; and
6. describe marketing tactics to grow your pharmacy.

February 4

ACPE #0129-9999-22-022-H07-P **0.1 CEU**

ACPE #0129-9999-22-022-H07-T **0.1 CEU**

Knowledge-based activity

USP <795> BUDs: An Update

Gus Bassani, PharmD

At the completion of this activity, the participant will be able to:

1. explain USP’s process for standard creation;
2. describe the background of the revisions proposed for USP <795>;
3. summarize the overview of the revisions proposed for USP <795>;
4. recognize where to find the proposed revisions to the chapters and the supplementary materials; and
5. discuss the next steps for the chapters.

ACPE #0129-9999-22-023-H07-P **0.1 CEU**

ACPE #0129-9999-22-023-H07-T **0.1 CEU**

Knowledge-based activity

USP <797> BUDs : An Update

Connie Sullivan

At the completion of this activity, the participant will be able to:

1. explain USP's process for standard creation;
2. describe the background for revisions proposed for USP <797>;
3. summarize the overview of revisions proposed for USP <797>;
4. recognize where to find the revisions proposed to the chapters and the supplementary materials; and
5. discuss the next steps for the chapters

ACPE #0129-9999-22-024-H07-P **0.1 CEU**

ACPE #0129-9999-22-024-H07-T **0.1 CEU**

Knowledge-based activity

The Biopharmaceutical Classification System: What You Should Know

Vanessa Pinheiro, Pharmacist Consultant

At the completion of this activity, the participant will be able to:

1. define the classes of the Biopharmaceutical Classification System (BCS);
2. recognize the importance of drug dissolution for absorption after oral administration of solid dosage forms;
3. identify excipients that could impact the dissolution of active pharmaceutical ingredients (APIs);
4. explain the considerations for formulation development when compounding from an API or an existing drug product; and
5. review the literature related to the BCS and compounding pharmacy.

ACPE #0129-9999-22-025-H07-P **0.1 CEU**

ACPE #0129-9999-22-025-H07-T **0.1 CEU**

Knowledge-based activity

USP: Minor Chapters, Major Impacts

Brian Kelley

At the completion of this activity, the participant will be able to:

1. outline Regulatory Considerations for USP Chapters and FDA guidelines;
2. explain USP <61> and USP <62> tests and how they determine if non-sterile products meet quality requirements;
3. recognize the significance of USP <51> preservative-effectiveness testing in compounding;
4. recognize the importance of a container closure system for a drug product and the critical protection it provides for stability and sterility; and
5. describe the test requirements for compounded preparations in USP <1163>

ACPE #0129-9999-22-026-H07-P 0.1 CEU

ACPE #0129-9999-22-026-H07-T 0.1 CEU

Application-based activity

BUDs & Stability Studies Under the Proposed New USP Chapters

Mindy Cormier, PharmD, R.Ph.

At the completion of this activity, the **pharmacist** participant will be able to:

1. review the discussion surrounding non-sterile and sterile beyond-use date appeals;
2. evaluate the importance of beyond-use dating for facilitating workflow efficiencies and patient access to personalized medicine;
3. identify new requirements for default and extended beyond use dating according to proposed USP <795> and <797>;
4. recognize what to look for in a stability-indicating study – verification, quality, independence, and much more; and
5. apply professional judgement in extrapolating stability data for extending beyond-use date.

At the completion of this activity, the **pharmacy technician** participant will be able to:

1. review the discussion surrounding non-sterile and sterile beyond-use date appeals;
2. evaluate the importance of beyond-use dating for facilitating workflow efficiencies and patient access to personalized medicine;
3. identify new requirements for default and extended beyond use dating according to proposed USP <795> and <797>; and
4. recognize what to look for in a stability-indicating study – verification, quality, independence, and much more.